Kaya, Ali HakanTekgunduz, EmreIlkkilic, KadirDal, Mehmet SinanMerdin, AlparslanKarakus, AbdullahHacioglu, Sibel Kabukcu2024-04-242024-04-2420181120-009X1973-9478https://doi.org/10.1080/1120009X.2017.1396017https://hdl.handle.net/11468/16924We hereby report our multicentre, retrospective experience with CLARA in patients with fludarabine/cytarabine/GCSF (FLAG) refractory AML. The study included all consecutive R/R AML patients, who received CLARA salvage during October 2010-October 2015 period. All patients were unresponsive to FLAG salvage chemotherapy regimen and did not undergo previous allo-HCT. A total of 40 patients were included. Following CLARA 5 (12.5%) patients experienced induction mortality and 10 (25%) patients achieved CR. 25 (62.5%) patients were unresponsive to CLARA. 7 (17.5%) out of 10 patients in CR received allo-HCT. Median overall survival of patients who achieved CR after CLARA was 24.5 months (8.5-54.5) and 3 months (2.5-5), in patients who underwent and didn't allo-HCT, respectively. Our results indicate that CLARA may be good alternative even in FLAG refractory AML patients and can be used as a bridge to allo-HCT, who have a suitable donor and able to tolerate the procedure.eninfo:eu-repo/semantics/closedAccessAcute Myeloid LeukaemiaAmlRelapseRefractoryClofarabineArticle3014448WOS:0004281546000062-s2.0-850328014212909895310.1080/1120009X.2017.1396017Q3Q4